In September of 2018, the FDA approved Epidiolex (Cannabidiol) Primer, the first plant-derived, purified pharmaceutical-grade cannabidiol (CBD) medication to treat Dravet syndrome or Lennox-Gastaut syndrome.
In February of 2020, FDA issued an opinion to encourage cannabis companies' development of cannabis products into prescription drugs through botanical drug development guidance for industry.
In July of 2020, the FDA developed a draft GFI "Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry."